We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

94 hedge funds and large institutions have $230M invested in Pacific Biosciences in 2015 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 29

7% less funds holding

Funds holding: 101 → 94 (-7)

32% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 19

33% less capital invested

Capital invested by funds: $342M → $230M (-$112M)

34% less call options, than puts

Call options by funds: $107K | Put options by funds: $162K

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
94
Holders Change
-7
Holders Change %
-6.93%
% of All Funds
2.51%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
13
Increased
32
Reduced
29
Closed
19
Calls
$107K
Puts
$162K
Net Calls
-$55K
Net Calls Change
-$342K

Top Buyers

1
CCM
Consonance Capital Management
New York
+$13.8M
2
NI
Numeric Investors
Massachusetts
+$5.4M
3
MC
Maverick Capital
Texas
+$4.15M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$3.25M
5
BIT
BlackRock Institutional Trust
California
+$2.59M

Top Sellers

1
DM
Deerfield Management
New York
-$14.3M
2
BA
BlackRock Advisors
Delaware
-$2.57M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.47M
4
BCM
Bridgeway Capital Management
Texas
-$1.95M
5
RG
Redmile Group
California
-$1.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
IG
26
ING Group
Netherlands
$1.46M – – –
SIM
27
Spark Investment Management
New York
$1.38M -$229K -33,200 -12%
TCIM
28
TIAA CREF Investment Management
New York
$1.19M -$25K -3,619 -2%
Deutsche Bank
29
Deutsche Bank
Germany
$1.09M +$162K +23,450 +14%
EIM
30
Essex Investment Management
Massachusetts
$877K -$7.65K -1,109 -0.7%
IHM
31
Iguana Healthcare Management
New York
$876K +$1.03M +150,000 New
BLAM
32
Bourne Lent Asset Management
New York
$862K +$1.02M +147,575 New
JP Morgan Chase
33
JP Morgan Chase
New York
$819K +$695K +100,855 +255%
GCP
34
GSA Capital Partners
United Kingdom
$812K +$740K +107,367 +340%
SO
35
STRS Ohio
Ohio
$755K +$542K +78,657 +155%
Renaissance Technologies
36
Renaissance Technologies
New York
$731K -$88.1K -12,772 -9%
Connor, Clark & Lunn Investment Management (CC&L)
37
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$689K -$761K -110,400 -48%
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$648K +$30.3K +4,400 +4%
WMSA
39
Weiss Multi-Strategy Advisers
New York
$642K +$18.6K +2,700 +3%
AQR Capital Management
40
AQR Capital Management
Connecticut
$641K -$252K -36,500 -25%
AllianceBernstein
41
AllianceBernstein
Tennessee
$531K -$38.6K -5,600 -6%
CLOS
42
Compagnie Lombard Odier SCmA
Switzerland
$514K -$27.6K -4,000 -4%
TMC
43
Trellus Management Company
Florida
$510K +$603K +87,400 New
PPA
44
Parametric Portfolio Associates
Washington
$508K -$289K -41,894 -33%
Charles Schwab
45
Charles Schwab
California
$500K – – –
TA
46
Teachers Advisors
New York
$488K – – –
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$450K +$75.2K +10,900 +16%
Goldman Sachs
48
Goldman Sachs
New York
$419K +$180K +26,091 +57%
ProShare Advisors
49
ProShare Advisors
Maryland
$413K +$76.3K +11,065 +19%
CS
50
Credit Suisse
Switzerland
$411K -$429K -62,147 -47%
1
2
3 4 5

PACB Hedge Fund Activity: Q1 2015 in Review

94 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2015, worth a combined $230M — down 33% from $342M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PACB and 13 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 32 added.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $13.8M. The largest seller was Deerfield Management, cutting an estimated $14.3M.

  • 94 institutional investors held Pacific Biosciences (PACB) as of Q1 2015, down from 101 in Q4 2014.
  • Funds reported $230M of Pacific Biosciences stock for Q1 2015, down 33% quarter-over-quarter.
  • 13 funds opened new Pacific Biosciences positions in Q1 2015 and 19 closed out, a net change of -6 holders.
  • The largest Pacific Biosciences buyer in Q1 2015 was Consonance Capital Management, an estimated $13.8M added.
  • The largest Pacific Biosciences seller in Q1 2015 was Deerfield Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q1 2015.